Structure-Based Development of 3,4-Fused Tricyclic Benzofuran Derivatives as Polyketide Synthase 13 Inhibitors with Negligible hERG Inhibition
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02635 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yu-Xin Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China No…. Hauptthemen laut MEDLINE: Benzofurans, Polyketide Synthases, ERG1 Potassium Channel. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Institute of Allergy and Infectious Diseases, National Natural Science Foundation of China.
Abstract (Originalsprache)
Polyketide synthase 13 (Pks13) is vital for synthesizing mycolic acid, which are essential for the survival of Mycobacterium tuberculosis (Mtb). Compounds that target Pks13 hold significant promise for developing new chemical entities for multidrug-resistant TB. The early lead benzofuran-3-carboxamide TAM16, demonstrated robust in vivo efficacy in murine models of tuberculosis infection; however, its further advancement was halted due to the cardiotoxicity associated with hERG inhibition. We implemented a conformational restriction strategy to explore the chemical space of 3,4-fused tricyclic benzofurans and indoles employing a structure-based design approach. Representative compounds were identified as Pks13-TE inhibitors, showing resistance against mutant strains from coumestan-resistant Mtb colonies. Notably, 29 and 30 exhibited potent antitubercular activity against Mtb H37Rv strain (MIC = 0.0156-0.0313 μg/mL), with negligible hERG inhibition (IC50 > 100 μM) suggesting that the 3,4-fused tricyclic benzofurans may present promising scaffold for developing Pks13-TE inhibitors without hERG liability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China.
- Center for Tuberculosis Research, Department of Medicine, Division of Infectious Disease, Johns Hopkins School of Medicine, Baltimore, Maryland 21231-1044, United States.
- Shanghai Key Laboratory of Green Chemistry and Chemical Process, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China.
ORCID-Profile: William R Bishai, Li-Fang Yu
Förderung
- National Institute of Allergy and Infectious Diseases
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y. X., Lun, S., Zhang, W., Tie, F. J., Cai, Y. P., Yang, F., Tang, J., Bishai, W. R., & Yu, L. F. (2025). Structure-Based Development of 3,4-Fused Tricyclic Benzofuran Derivatives as Polyketide Synthase 13 Inhibitors with Negligible hERG Inhibition. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02635
Vancouver
Zhou YX, Lun S, Zhang W, Tie FJ, Cai YP, Yang F, et al. Structure-Based Development of 3,4-Fused Tricyclic Benzofuran Derivatives as Polyketide Synthase 13 Inhibitors with Negligible hERG Inhibition. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02635
BibTeX
@article{Zhou2025,
author = {Zhou, Yu-Xin and Lun, Shichun and Zhang, Wei and Tie, Fa-Jin and Cai, Yan-Peng and Yang, Fan and Tang, Jie and Bishai, William R and Yu, Li-Fang},
title = {Structure-Based Development of 3,4-Fused Tricyclic Benzofuran Derivatives as Polyketide Synthase 13 Inhibitors with Negligible hERG Inhibition},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02635}
}
EUVIMED